Literature DB >> 6644573

Determination of busulfan in plasma by GC-MS with selected-ion monitoring.

H Ehrsson, M Hassan.   

Abstract

A GC-MS technique with selected-ion monitoring is described for the determination of busulfan in plasma. Busulfan is extracted from plasma with methylene chloride and converted to 1,4-diiodobutane. Analysis by GC-MS with selected-ion monitoring (m/z 183) gave a relative standard deviation of +/- 4.3% (n = 5) at the 10-ng/ml level.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6644573     DOI： 10.1002/jps.2600721024

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN： 0022-3549            Impact factor:   3.534


  7 in total

Review 1.  The role of busulfan in bone marrow transplantation.

Authors:  M Hassan
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

2.  Gas-chromatographic analysis of busulfan for therapeutic drug monitoring.

Authors:  L Embree; R B Burns; J R Heggie; G L Phillips; D E Reece; J J Spinelli; D O Hartley; N J Hudon; J H Goldie
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics.

Authors:  M Hassan; G Oberg; M Björkholm; I Wallin; M Lindgren
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Metabolism of 14C-busulfan in isolated perfused rat liver.

Authors:  M Hassan; H Ehrsson
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Jan-Mar       Impact factor: 2.441

Review 5.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. General considerations, the nitrosoureas and alkylating agents.

Authors:  A G Bosanquet
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  Pharmacokinetics of high-dose busulfan in children.

Authors:  G Vassal; A Gouyette; O Hartmann; J L Pico; J Lemerle
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

7.  Flavin-containing monooxygenase 3 (FMO3) role in busulphan metabolic pathway.

Authors:  Ibrahim El-Serafi; Ylva Terelius; Manuchehr Abedi-Valugerdi; Seán Naughton; Maryam Saghafian; Ali Moshfegh; Jonas Mattsson; Zuzana Potácová; Moustapha Hassan
Journal:  PLoS One       Date:  2017-11-09       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.